BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer

Rajesh M Valanparambil; Lilin Lai; Margaret A Johns; Meredith Davis-Gardner; Susanne L Linderman; Tarrant Oliver McPherson; Andres Chang; Akil Akhtar; Estefany L Bocangel Gamarra; Hayley Matia; Ashley A McCook-Veal; Jeffrey Switchenko; Tahseen H Nasti; Felicia Green; Manpreet Saini; Andreas Wieland; Benjamin A Pinsky; Daniel Solis; Madhav V Dhodapkar; Jennifer Carlisle; Suresh Ramalingam; Rafi Ahmed; Mehul S Suthar

doi:10.1038/s41541-023-00779-8

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer

NPJ Vaccines. 2023 Nov 21;8(1):179. doi: 10.1038/s41541-023-00779-8.

Authors

Rajesh M Valanparambil^{1

2}, Lilin Lai^{1

3

4}, Margaret A Johns⁵, Meredith Davis-Gardner^{1

3

4}, Susanne L Linderman^{1

2}, Tarrant Oliver McPherson^{6

7}, Andres Chang^{1

2

5

8}, Akil Akhtar^{1

2}, Estefany L Bocangel Gamarra^{1

2}, Hayley Matia⁵, Ashley A McCook-Veal^{6

7}, Jeffrey Switchenko^{6

7}, Tahseen H Nasti^{1

2}, Felicia Green⁵, Manpreet Saini^{1

2}, Andreas Wieland^{1

2

9

10}, Benjamin A Pinsky¹¹, Daniel Solis¹¹, Madhav V Dhodapkar^{5

8}, Jennifer Carlisle⁵, Suresh Ramalingam^#⁵, Rafi Ahmed^#^{1

2}, Mehul S Suthar^#^{12

13

14

15}

Affiliations

¹ Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
² Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
³ Department of Pediatrics, Emory University, Atlanta, GA, USA.
⁴ Emory National Primate Center, Atlanta, GA, USA.
⁵ Winship Cancer Institute of Emory University, Atlanta, GA, USA.
⁶ Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, USA.
⁷ Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, USA.
⁸ Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
⁹ Department of Otolaryngology, The Ohio State University, Columbus, OH, USA.
¹⁰ Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, OH, USA.
¹¹ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
¹² Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA. mehul.s.suthar@emory.edu.
¹³ Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA. mehul.s.suthar@emory.edu.
¹⁴ Department of Pediatrics, Emory University, Atlanta, GA, USA. mehul.s.suthar@emory.edu.
¹⁵ Emory National Primate Center, Atlanta, GA, USA. mehul.s.suthar@emory.edu.

^# Contributed equally.

Abstract

This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4-6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.

Abstract

Grants and funding